Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — DNB Nordic Healthcare Conference 2023
17 slides from Gentian Diagnostics Asa's conference presentation, Dec 14, 2023
Slide 1: DNB’s Nordic Healthcare Conference
DNB’s Nordic Healthcare Conference Hilja Ibert, CEO 14 December 2023
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole which are subject to risks, uncertainties and other factors with applicable laws and regulations. The Company require responsibility of Gentian Diagnostics ASA (the “Company” that may cause actual events to differ materially fro
Slide 3: Efficient diagnostics for better treatment decisions
Efficient diagnostics for better treatment decisions
Slide 4: High-impact diagnostics with global commercial traction
High-impact diagnostics with global commercial traction Sales office, Sweden HQ, Norway Sales office, US Rep. office, China Total revenue 2022 4Y-CAGR Oslo listing Market cap MNOK 112 28% OSE: GENT MNOK ~600 Note: Market cap as per close on 11 December 2023.
Slide 5: Attractive value proposition: fast results at lower cost
Attractive value proposition: fast results at lower cost The IVD market challenge Gentian’s solution High-value benefits Many of the existing, but clinically Gentian converts existing biomarkers relevant biomarkers are available only to the most efficient automated, high- Faster results leading to b
Slide 6: Strategy with focus on profitable sales growth
Strategy with focus on profitable sales growth 8* tests contributing Industry-leading to saving costs and team and knowhow protecting life Team with proven track- USD 1.8bn serviceable record and industry market with 5-10% annual expertise from market growth leading IVD companies Entered partnership
Slide 7: Products targeting important disease groups
Products targeting important disease groups ESTABLISHED PRODUCTS IN MARKET DEVELOPMENT IN PRODUCT DEVELOPMENT Lifestyle Inflammation Pancreas Inflammation Cardiac Kidney disease Inflammation associated Inflammation & infection deficiency & infection disease diseases Cystatin C Canine CRP fCAL® fPELA
Slide 8: Positioned for strong value creation: high growth and scalability
Positioned for strong value creation: high growth and scalability Enabling 40% long-term EBITDA margin Monthly sales revenue 3Q19-3Q23 Commercial traction Revenue potential by product group LTM, MNOK As per 3Q23 2028 125 • Commercial interest for 100 >2x Gentian NT-proBNP in optimisation • Two poten
Slide 9: Continued strong sales growth with stable cost base
Continued strong sales growth with stable cost base 3yr CAGR 29.5% at 3Q23 Sales revenue year to date 2023 vs 2022 Strong cost discipline maintained MNOK OPEX Capitalised R&D expenses 97,7 1 2 1 1 1 +33% 73,7 18 19 19 18 17 2022 2023 3Q22 4Q22 1Q23 2Q23 3Q23
Slide 10: Operational leverage and long-term contracts
Operational leverage and long-term contracts Sticky revenues with high transition costs Costs ex R&D Revenue source % of sales revenue % of sales revenue 3Q23 69% 47% 37% 56% 52% 81% 48% 2018 2022 YTD 2023 COGS Other OPEX Long-term contracts Spot sales Stable cost development and completed plant exp
Slide 11: Long-term ambitions rooted in recent progress
Long-term ambitions rooted in recent progress Five established products with potential to grow 20%+ annually Prove clinical relevance of GCAL and bring NT-proBNP to market 7 products with combined net revenue potential of Bring a steady stream of new high-impact diagnostic tests to market NOKUnriske
Slide 12: Q&A
Q&A
Slide 13: Appendix
Appendix
Slide 14: P&L highlights
P&L highlights MNOK 3Q23 3Q22 YTD23 YTD22 2022 Sales 32.1 23.1 97.7 73.7 101.6 Other revenues 2.7 2.0 6.9 7.3 10.3 Total revenues 34.8 25.1 104.5 81.1 111.9 COGS -16.3 -12.8 -46.2 -38.8 -52.6 Employee benefit expenses -13.0 -10.0 -35.4 -30.1 -40.9 D&A -2.4 -2.7 -7.1 -7.5 -10.2 Other OPEX -4.3 -8.4 -
Slide 15: Cash flow highlights
Cash flow highlights MNOK 3Q23 3Q22 YTD23 YTD22 2022 Operating activities -2.0 4.7 1.8 -5.5 -14.0 Investing activities -1.2 -1.8 -3.3 -12.3 -14.7 Financing activities -1.1 -1.1 -3.4 -3.2 -4.3 Changes in cash and cash equivalent -4.3 -1.8 -5.0 -21.1 -32.9 Cash and cash equivalent at the beginning of
Slide 16: Board of directors
Board of directors Tomas Espen T. Kari E. Kjersti Fredrik Monika Frank Settevik Jørgensen Krogstad Grimsrud Thoresen Neuman Frantzen Chair of Board member Board member Board member Board member Board member Board member the Board Tomas Settevik has Espen Tidemann Kari Krogstad has Kjersti Grimsrud i
Slide 17: Top 20 shareholders
Top 20 shareholders Shareholder No of shares % Vatne Equity AS 2 110 224 13.68 % Kvantia AS 1 623 368 10.53 % Holta Invest AS 1 228 502 7.97 % Verdipapirfondet Delphi Nordic 987 104 6.40 % Safrino AS 749 700 4.86 % Carpe Diem Afseth AS 544 089 3.53 % Skandinaviska Enskilda Banken AB 501 000 3.25 % V
Gentian Diagnostics — DNB Nordic Healthcare Conference 2023 on 6ix